Abstract Number: 1700 • ACR/ARHP Annual Meeting 2018
Remission and Low Disease Activity State Prevent Hospitalizations and Emergency Room Visits in Systemic Lupus Erythematosus Patients
Background/Purpose: Although the survival rate of patients with Systemic Lupus Erythematosus (SLE) has improved over the years, patients are frequently hospitalized or evaluated in the…Abstract Number: 2929 • ACR/ARHP Annual Meeting 2018
Validation of Remission and Lupus Low Disease Activity State As Predictors of Organ Damage in SLE
Background/Purpose: Outcome measures that combine control of SLE activity and prednisone reduction are clinically relevant. A clinical goal in SLE is to reduce risk of…Abstract Number: 745 • ACR/ARHP Annual Meeting 2018
Prolonged Remission and Influence on Damage Accrual and Infection for Patients with Systemic Lupus Erythematosus: A Multi-Center Cohort Study from China
Prolonged Remission and Influence on Damage Accrual and Infection for Patients with Systemic Lupus Erythematosus: a Multi-center Cohort Study from ChinaZiqian Wang1, Jiuliang Zhao1, Yanhong…Abstract Number: 1684 • ACR/ARHP Annual Meeting 2018
Prolonged Remission/Low Disease Activity State Is Associated with a Better Health-Related Quality
Background/Purpose: Achieving remission and low lupus disease activity state (LDAS) in systemic lupus erythematosus (SLE) patients improves their prognosis in terms of damage accrual. But,…Abstract Number: 1691 • ACR/ARHP Annual Meeting 2018
Application of the Doris Algorithm for the Definition of Disease Remission and Its Relation with Damage Accrual over a 2-Year Period in a Cohort of Italian Patients with Systemic Lupus Erythematosus Classified According to Clinical Disease Patterns
Background/Purpose: Systemic Lupus Erythematosus (SLE) is characterized by a fluctuating course. To achieve sustained remission is the ultimate goal of maintenance treatment. However the definition…Abstract Number: 1779 • ACR/ARHP Annual Meeting 2016
Remission and Low Lupus Disease Activity Status (LLDAS) Protect Lupus Patients from Damage Occurrence: Data from a Multi-Ethnic, Multinational Latin American Lupus Cohort
Background/Purpose: Recently, definitions of both Remission and LLDAS have been proposed which include disease activity status and medication intake [immunosuppressive (IS) drugs and corticosteroids]. The…Abstract Number: 1805 • ACR/ARHP Annual Meeting 2016
Factors Associated with Complete Remission in Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study in One Center
Background/Purpose: Systemic lupus erythematosus (SLE) is characterized by disease flares, alternated with periods of clinical remission. In the past years, the “treat-to-target” strategy in SLE…Abstract Number: 2938 • ACR/ARHP Annual Meeting 2015
Baseline Predictors of Remission and Low Disease Activity Using Recently Defined International Criteria in a Multi-Center Lupus Registry Cohort
Background/Purpose: Treating to a target of remission or low disease activity state (LDAS) is an attractive potential therapeutic approach in SLE. Recently, LDAS and remission…Abstract Number: 1566 • ACR/ARHP Annual Meeting 2013
Consensus Definition and Preliminary Validation Of a Low Disease Activity State In Systemic Lupus Erythematosus
Background/Purpose: The definitions of low disease activity state (LDAS) and remission as desirable treatment goals in rheumatoid arthritis have been widely applied in research and…Abstract Number: 679 • ACR/ARHP Annual Meeting 2012
ZAP70+ B Cells and Plasmablasts As Markers of Disease Activity and Remission in Systemic LUPUS Erythematosus Nephritis
Background/Purpose: To analyze differences in B cells subsets distribution in patients with renal systemic lupus erythematosus (SLE). To define possible cellular biomarkers of active nephritis…
ACR Meeting Abstracts